Aethlon Medical (AEMD) Scheduled to Post Quarterly Earnings on Wednesday

Aethlon Medical (NASDAQ:AEMDGet Free Report) is set to release its earnings data after the market closes on Wednesday, February 14th. Analysts expect Aethlon Medical to post earnings of ($1.32) per share for the quarter. Persons that are interested in participating in the company’s earnings conference call can do so using this link.

Aethlon Medical (NASDAQ:AEMDGet Free Report) last posted its quarterly earnings data on Tuesday, November 14th. The medical equipment provider reported ($1.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.35) by $0.13. On average, analysts expect Aethlon Medical to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

Aethlon Medical Price Performance

NASDAQ:AEMD opened at $1.75 on Tuesday. The firm has a market capitalization of $4.36 million, a price-to-earnings ratio of -0.36 and a beta of 1.88. Aethlon Medical has a 1 year low of $1.40 and a 1 year high of $7.20. The business has a 50 day simple moving average of $1.94 and a 200-day simple moving average of $2.17.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. Two Sigma Investments LP purchased a new position in Aethlon Medical during the 3rd quarter worth $32,000. Renaissance Technologies LLC purchased a new position in Aethlon Medical during the 3rd quarter worth $36,000. HRT Financial LP purchased a new position in Aethlon Medical during the 4th quarter worth $28,000. Citadel Advisors LLC purchased a new position in shares of Aethlon Medical in the 3rd quarter valued at $72,000. Finally, Jane Street Group LLC increased its holdings in shares of Aethlon Medical by 895.7% in the 4th quarter. Jane Street Group LLC now owns 140,245 shares of the medical equipment provider’s stock valued at $39,000 after acquiring an additional 126,160 shares during the period. 3.02% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on AEMD. StockNews.com began coverage on Aethlon Medical in a research note on Thursday, February 8th. They issued a “sell” rating for the company. HC Wainwright reduced their price target on Aethlon Medical from $90.00 to $23.00 and set a “buy” rating on the stock in a report on Tuesday, October 24th.

View Our Latest Research Report on AEMD

About Aethlon Medical

(Get Free Report)

Aethlon Medical, Inc, a medical therapeutic company, focuses on developing products to treat cancer and life-threatening infectious diseases in the United States. It develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system.

Further Reading

Earnings History for Aethlon Medical (NASDAQ:AEMD)

Receive News & Ratings for Aethlon Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aethlon Medical and related companies with MarketBeat.com's FREE daily email newsletter.